PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-100.00%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
-83.05%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
7.21%
Positive EBIT growth while AGEN is negative. John Neff might see a substantial edge in operational management.
7.21%
Positive operating income growth while AGEN is negative. John Neff might view this as a competitive edge in operations.
7.01%
Positive net income growth while AGEN is negative. John Neff might see a big relative performance advantage.
8.82%
Positive EPS growth while AGEN is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
8.82%
Positive diluted EPS growth while AGEN is negative. John Neff might view this as a strong relative advantage in controlling dilution.
0.91%
Share reduction more than 1.5x AGEN's 9.00%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
0.91%
Diluted share reduction more than 1.5x AGEN's 9.00%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
No Data
No Data available this quarter, please select a different quarter.
1.55%
OCF growth under 50% of AGEN's 5.47%. Michael Burry might suspect questionable revenue recognition or rising costs.
1.40%
Positive FCF growth while AGEN is negative. John Neff would see a strong competitive edge in net cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative 3Y CAGR while AGEN stands at 17.52%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
91.07%
10Y OCF/share CAGR above 1.5x AGEN's 53.18%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
81.18%
Positive OCF/share growth while AGEN is negative. John Neff might see a comparative advantage in operational cash viability.
13.88%
3Y OCF/share CAGR under 50% of AGEN's 56.06%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
98.43%
Positive 10Y CAGR while AGEN is negative. John Neff might see a substantial advantage in bottom-line trajectory.
78.58%
Positive 5Y CAGR while AGEN is negative. John Neff might view this as a strong mid-term relative advantage.
-7.39%
Negative 3Y CAGR while AGEN is 43.30%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
109.82%
Positive growth while AGEN is negative. John Neff might see a strong advantage in steadily compounding net worth over a decade.
14.99%
Below 50% of AGEN's 34.52%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
-59.15%
Negative 3Y equity/share growth while AGEN is at 47.77%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
8.48%
Positive asset growth while AGEN is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
19.47%
Positive BV/share change while AGEN is negative. John Neff sees a clear edge over a competitor losing equity.
-6.20%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
-18.94%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
28.45%
We expand SG&A while AGEN cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.